GangliotriosylceramideGangliotriosylceramide
Move your mouse over image or click to enlarge

Gangliotriosylceramide

Asialo-GM2; Gg3

Gangliosides are being actively studied in many laboratories due to their involvement in numerous diseases. One of the most important examples of these diseases is the unusual accumulation of various gangliosides in tumor cells. This has led many researchers to explore ways to combat tumors using gangliosides and antibodies to gangliosides. Lymphoma has been shown to have an increased level of asialo-GM2 and passive immunization with monoclonal immunoglobulin G3 antibodies to asialo-GM2 has effectively suppressed tumor formation in these cells.1 Asialo-GM2 has been identified as a receptor for many types of bacteria including Neisseria gonorrhoeae and Haemophilus influenzae. In the metabolism of asialo-GM2, the same enzyme that synthesizes GD2 and GM2 (beta-1,4 N-Acetylgalactosaminyltransferase) is also responsible for the synthesis asialo-GM2.2
Cat# Size Price Qty Buy
1512 100 ug £590.63

Additional Information

Property Value or Rating
Product Size 100 ug
Manufacturer Matreya, LLC
Empirical Formula C56H104N2O18 (stearoyl)
CAS# 35960-33-9
Formula Weight 1093.4
Source semisynthetic
Purity 98+%
Analytical Methods TLC, identity confirmed by MS
Natural Source Semi-synthetic|Human
Solubility chloroform/methanol/DI water, 2:1:0.1; forms micellar solution in water
Physical Appearance A neat solid
Storage -20°C
References

1. W. Young Jr and S. Hakomori “Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo” Science, Vol. 211:4481 pp. 487-489, 1981 
2. Young et al. “Cloned ß1,4 N-Acetylgalactosaminyltransferase Synthesizes GA2 as well as Gangliosides GM2 and GD2” Journal of Biological Chemistry, Vol. 269:46 pp. 29227-29231, 1994

Related Documents